By Elric Langton | 30th November 2021
Today's results from SkinBioTherapeutics Plc (SBTX) were never going to set the world alight; after all, the company's first commercial product, AxisBiotix Ps, was launched just four weeks ago. Neither did any of us expect the bloodbath to follow; it is utterly bonkers, and frankly, a measure of the naivety of a larg…
